Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viking Thera (NQ: VKTX ) 51.71 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Viking Thera < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon. July 22, 2024 Eli Lilly is still a smart pick, but these two stocks could grow more in the near term. Via The Motley Fool 3 Monster Stocks in the Making to Buy Right Now July 20, 2024 They're small now, but these stocks could grow much larger. Via The Motley Fool Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review July 19, 2024 The Nasdaq tumbled amid chip woes. Via Investor's Business Daily 3 Undervalued Biotech Stocks With Breakout Potential July 19, 2024 Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements Via InvestorPlace Smart Money Is Betting Big In VKTX Options July 18, 2024 Via Benzinga Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity July 05, 2024 Via Benzinga Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today July 01, 2024 Via Benzinga Is Viking Therapeutics a Millionaire-Maker? July 19, 2024 This biotech stock fits the profile of a potentially big winner to a T. Via The Motley Fool EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' July 18, 2024 Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. Via Benzinga 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition July 18, 2024 These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. Via InvestorPlace Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? July 17, 2024 Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... Via Benzinga Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 17, 2024 Via Benzinga Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' July 17, 2024 Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. Via Benzinga Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data July 17, 2024 Roche released early-stage data on its oral weight-loss drug. Via Investor's Business Daily Is Viking Therapeutics the Best Biotech Stock for You? July 17, 2024 Let's look beyond the hype the company is generating this year. Via The Motley Fool The 3 Most Undervalued Biotech Stocks to Buy in July 2024 July 12, 2024 There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. Via InvestorPlace Is Viking Therapeutics Stock Running Out of Steam? July 11, 2024 Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today. Via The Motley Fool Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics July 10, 2024 Both competitors have promising lead programs, and enough cash, too. Via The Motley Fool Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug July 09, 2024 Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been Via MarketBeat Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half? July 09, 2024 This pharma company is posting double-digit revenue growth. Via The Motley Fool 3 Overlooked Giants-in-the-Making for Patient Investors July 08, 2024 Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. Via InvestorPlace The 7 Best Under $10 Stocks to Buy in July 2024 July 06, 2024 We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. Via InvestorPlace Forget Eli Lilly: 3 Biotech Stocks to Buy Instead July 04, 2024 Eli Lilly is a good stock to buy, but these should be even better. Via The Motley Fool S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday? July 03, 2024 The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities 3 Biotech Moonshots With Imminent Catalyst Potential July 03, 2024 Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts. Via InvestorPlace Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? July 03, 2024 Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases Via MarketBeat Exposures Product Safety Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes July 02, 2024 Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy Via MarketBeat Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market July 01, 2024 Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Via MarketBeat Exposures Product Safety Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year? July 01, 2024 It's a tough act to follow. Via The Motley Fool 3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics June 30, 2024 While their share prices have traveled different paths recently, the similarity between the two companies is striking. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.